Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions

Imran, Mohd; Khan, Shah Alam; Alshammari, Mohammed Kanan; Alreshidi, Meshal Ayedh; Alreshidi, Abeer Abdullah; Alghonaim, Rawan Sulaiman; Alanazi, Fayez Aboud; Alshehri, Sultan; Ghoneim, Mohammed M.; Shakeel, Faiyaz

doi:10.3390/biomedicines9121938

Cited by 16 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patent literature search was performed on Sci-Finder, Espacenet, Patentscope, and USPTO databases on June 27, 2022 [51] , [52] , [53] , [54] , [55] . The keywords “selenium + COVID-19” and “selenium + SARS-CoV-2” were selected for patent searching on different patent databases (Espacenet, USPTO, Scifinder, and Patentscope).…”

Section: Seleniummentioning

confidence: 99%

Selenium and COVID-19: A spotlight on the clinical trials, inventive compositions, and patent literature

Alshammari¹,

Fatima²,

Alraya³

et al. 2022

Journal of Infection and Public Health

Self Cite

View full text Add to dashboard Cite

Section: Seleniummentioning

confidence: 99%

Selenium and COVID-19: A spotlight on the clinical trials, inventive compositions, and patent literature

Alshammari¹,

Fatima²,

Alraya³

et al. 2022

Journal of Infection and Public Health

Self Cite

View full text Add to dashboard Cite

“…The patent search was performed on 8 March 2022, employing different patent databases described in the literature [38][39][40][41][42], using the combination terms "Quercetin + COVID-19" and "Quercetin + SARS-CoV-2". The patent database, Espacenet (quercetin + COVID-19 = 45 hits and quercetin + SARS-CoV-2 = 47 hits), Sci-Finder (quercetin + COVID-19 = 47 hits and quercetin + SARS-CoV-2 = 18 hits), USPTO (quercetin + COVID-19 = 31 hits and quercetin + SARS-CoV-2 = 29 hits), and Patentscope (quercetin + COVID-19 = 44 hits and quercetin + SARS-CoV-2 = 45 hits) revealed many patents and patent applications (Table 2).…”

Section: Patent Searchingmentioning

confidence: 99%

The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature

et al. 2022

Self Cite

View full text Add to dashboard Cite

Quercetin is a phenolic flavonol compound with established antioxidant, anti-inflammatory, and immuno-stimulant properties. Recent studies demonstrate the potential of quercetin against COVID-19. This article highlighted the prophylactic/therapeutic potential of quercetin against COVID-19 in view of its clinical studies, inventions, and patents. The literature for the subject matter was collected utilizing different databases, including PubMed, Sci-Finder, Espacenet, Patentscope, and USPTO. Clinical studies expose the potential of quercetin monotherapy, and also its combination therapy with other compounds, including zinc, vitamin C, curcumin, vitamin D3, masitinib, hydroxychloroquine, azithromycin, and ivermectin. The patent literature also examines claims that quercetin containing nutraceuticals, pharmaceuticals, and dietary supplements, alone or in combination with other drugs/compounds, including favipiravir, remdesivir, molnupiravir, navitoclax, dasatinib, disulfiram, rucaparib, tamarixin, iota-carrageenan, and various herbal extracts (aloe, poria, rosemary, and sphagnum) has potential for use against COVID-19. The literature reveals that quercetin exhibits anti-COVID-19 activity because of its inhibitory effect on the expression of the human ACE2 receptors and the enzymes of SARS-CoV-2 (MPro, PLPro, and RdRp). The USFDA designated quercetin as a “Generally Recognized as Safe” substance for use in the food and beverage industries. It is also an inexpensive and readily available compound. These facts increase the possibility and foreseeability of making novel and economical drug combinations containing quercetin to prevent/treat COVID-19. Quercetin is an acidic compound and shows metabolic interaction with some antivirals, antibiotics, and anti-inflammatory agents. Therefore, the physicochemical and metabolic drug interactions between quercetin and the combined drugs/compounds must be better understood before developing new compositions.

show abstract

“…The patent exploration was carried out utilizing different patent databases (Sci-Finder, Espacenet, Patentscope, and the USPTO) [ 34 , 35 , 36 , 37 , 38 , 39 , 40 ] on 31 January 2022. A combination search for the terms “Zinc + COVID-19” and “Zinc + SARS-CoV-2” was performed in different fields (claims, abstract, and title) of Espacenet, Patentscope, and the USPTO.…”

Section: Patent Searchingmentioning

confidence: 99%

Development of Therapeutic and Prophylactic Zinc Compositions for Use against COVID-19: A Glimpse of the Trends, Inventions, and Patents

et al. 2022

Self Cite

View full text Add to dashboard Cite

Zinc is an essential nutrient for human health; it is involved in the catalytic, structural, and regulatory functions of the human cellular system. Different compositions of zinc, as well as its pharmaceutically acceptable salts, are available on the market. Recent studies have demonstrated the role of zinc in combating COVID-19. It has been determined that zinc prevents the entry of SARS-CoV-2 into cells by lowering the expression of ACE-2 receptors and inhibiting the RNA-dependent RNA polymerase of SARS-CoV-2. Zinc also prevents the cytokine storm that takes place after the entry of SARS-CoV-2 into the cell, via its anti-inflammatory activity. The authors believe that no study has yet been published that has reviewed the trends, inventions, and patent literature of zinc compositions to treat/prevent COVID-19. Accordingly, this review has been written in order to fill this gap in the literature. The information about the clinical studies and the published patents/patent applications was retrieved from different databases. This review covers patent literature on zinc compositions up to 31 January 2022. Many important patents/patent applications for zinc-based compositions filed by innovative universities and industries were identified. The patent literature revealed zinc compositions in combination with zinc ionophores, antioxidants, antivirals, antibiotics, hydroxychloroquine, heparin, ivermectin, and copper. Most of these studies were supported by clinical trials. The patent literature supports the potential of zinc and its pharmaceutical compositions as possible treatments for COVID-19. The authors believe that countless zinc-based compositions are still unexplored, and there is an immense opportunity to evaluate a considerable number of the zinc-based compositions for use against COVID-19.

show abstract

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions

Cited by 16 publications

References 39 publications

Selenium and COVID-19: A spotlight on the clinical trials, inventive compositions, and patent literature

Selenium and COVID-19: A spotlight on the clinical trials, inventive compositions, and patent literature

The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature

Development of Therapeutic and Prophylactic Zinc Compositions for Use against COVID-19: A Glimpse of the Trends, Inventions, and Patents

Contact Info

Product

Resources

About